Clinical significance of <i>MLH1</i>/<i>MSH2</i> for stage II/III sporadic colorectal cancer.

World J Gastrointest Oncol · 2019 · PMC6883179 · PMID 31798786

Europe PMC DOI

hedged sentences

0.0010

closest p · 0.0× alpha

0.0520

boldest claim

The sentences

a favorable trendP < 0.001actually significant

Patients with MLH1/MSH2 -negative stage II or III CRC showed a favorable trend for OS (68.62 ± 0.83 vs 62.11 ± 1.07 mo, P < 0.001).

also in 1,335 other papers

a nonsignificant trendP = 0.052so close (0.05 < p ≤ 0.1)

But a nonsignificant trend for survival benefit from adjuvant chemotherapy was observed in patients with MLH1/MSH2 -positive stage III disease (multivariate P = 0.052, HR = 2.817, 95%CI 0.223-6.671) (Table 4 ).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.